CDCM 5th Annual Symposium

8:30-8:35

Open Zoom-Waiting Room

8:35-8:55

Opening remarks:    Lloyd Minor, MD, Dean, School of Medicine, Stanford University 

David Entwistle, President and CEO, Stanford Health Care

Paul King, President and CEO, Stanford Children’s Health 

Irv Weissman, MD, Director, Institute of Stem Cell Biology and Regenerative Medicine, Stanford University

8:55-9:00

Maria Grazia Roncarolo, MD, Director, CDCM, Stanford University

Opening Keynote:

9:00-9:45

Introduction of Keynote: Anthony Oro, MD, PhD, Co-Director, CDCM, Stanford University

Keynote: Deepak Srivastava, MD, President, Gladstone Institutes, Director, Roddenberry Stem Cell Center at Gladstone and Professor, University of California San Francisco

Title: “Cellular Reprogramming Approaches for Human Disease”

Session 1

9:50-10:15

Vittorio Sebastiano, PhD, Assistant Professor Obstetrics and Gynecology, Institute of Stem Cell Biology and Regenerative Medicine, Stanford University

Title: “Epigenetic Reprogramming of Aging: Curative Implications for the Elderly”

10:15-10:40

Kristy Red-Horse, PhD, Associate Professor of Biology, Institute of Stem Cell Biology and Regenerative Medicine, Stanford University

Title: "Comparing Coronary Artery Development in Mouse and Human"

10:40-10:55

Break

Session 2

10:55-11:20

Michael A. Fischbach, PhD, Associate Professor, Department of Bioengineering and Medicine, Stanford University

Title: "Small Molecules from the Human Microbiota"

11:20-11:45

Hiro Nakauchi, MD, PhD, Professor of Genetics, Institute of Stem Cell Biology and Regenerative Medicine, Stanford University

Title: “Ex vivo expansion of HSCs: towards a holy grail in hematology”

11:50-12:30

LUNCH BREAK: “Talk to the CDCM Experts” 

Rosa Bacchetta- “Why gene therapy for IPEX syndrome to treat autoimmunity?”

Natalia Gomez-Ospina- “Hematopoietic Stem Cell Transplantation of Genome-edited Cells for Neurological Diseases”

Bertha Chen- “Challenges with Translation of Mesenchymal Cell Therapies”

Agnieszka Czechowicz- “Progress Towards Safe, Curative Treatment of Blood and Immune Diseases: Development of Novel Conditioning Regimens for Hematopoietic Cell Transplantation”

Alice Bertaina- “Graft Engineering for Treating Malignant and Non-Malignant Disorders”

Fraser Wright- “AAV Gene Therapy Vectors – Optimizing Design to Address Immune Barriers”

Neehar Bhatia- “cGMP Manufacturing of Cell and Gene Therapies: Overcoming the Challenges”

Keynote:

12:30-1:15

Introduction of Keynote: Maria T. Millan, MD, President and CEO, California Institute for Regenerative Medicine (CIRM)

Robert Klein, Founder, Chairman, Americans for Cures

Title: “Funding the Future of Medical Research and clinical Trials”

Session 3

1:20-1:45

Steven A. Feldman, PhD, Director of Manufacturing and Process Development, Stanford Center for Cancer Cell Therapy, Stanford University

Title: “Manufacturing and Characterization of Bispecific CD19/22 CAR T Cells for the Treatment of B Cell Malignancies”

1:45-2:10

Zhaohui Ye, PhD, Office of Tissues and Advanced Therapies, Division of Cellular and Gene Therapies, Gene Transfer and Immunogenicity Branch, Food and Drug Administration

Title: “Challenges in Stem Cell-Based Gene Therapy Product Characterization”

Closing Keynote:

2:10-2:55

Introduction of Keynote: Fraser Wright, PhD, Director of Technology Innovation, CDCM, Stanford University

Keynote: Beverly L. Davidson, PhD, Director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children’s Hospital of Philadelphia

Title: “Advancing Gene-Based Medicines for the Brain”

2:55-3:00

Closing Remarks: Matthew Porteus, MD, PhD, Co-Director, CDCM, Stanford University